Company Description
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.
It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue.
It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 12, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Geoffrey Dow |
Contact Details
Address: 1025 Connecticut Avenue NW, Suite 1000 Washington, District of Columbia 20036 United States | |
| Phone | 202 327 5422 |
| Website | 60degreespharma.com |
Stock Details
| Ticker Symbol | SXTP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.30 |
| CIK Code | 0001946563 |
| CUSIP Number | 83006G104 |
| ISIN Number | US83006G1040 |
| Employer ID | 45-2406880 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Geoffrey Stuart Dow Ph.D. | Chairman, Chief Executive Officer and President |
| Tyrone Miller | Chief Financial Officer and Treasurer |
| Kristen Landon | Chief Commercial Officer |
| Dr. Bryan Smith | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 9, 2025 | 8-K | Current Report |
| Sep 5, 2025 | 424B5 | Filing |
| Sep 5, 2025 | 8-K | Current Report |
| Sep 2, 2025 | DEFR14A | Filing |
| Aug 27, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 15, 2025 | PRE 14A | Other preliminary proxy statements |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Jul 22, 2025 | SCHEDULE 13G | Filing |
| Jul 18, 2025 | SCHEDULE 13G | Filing |
| Jul 18, 2025 | 8-K | Current Report |